Clinical, MRI, and CSF markers of disability progression in multiple sclerosis

Disease Markers

Volumn 35, Issue 6, 2013, Pages 687-699

  Gajofatto, Alberto ^a   Calabrese, Massimiliano ^a   Benedetti, Maria Donata ^a   Monaco, Salvatore ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROSPINAL FLUID; CLINICAL FEATURE; DISEASE COURSE; DISEASE MARKER; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; BRAIN; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PROGNOSIS;

EID: 84896974447     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/484959     Document Type: Review

References (134)

1. B. D. Trapp, J. Peterson, R. M. Ransohoff, R. Rudick, S. Mörk, and L. Bö, and "Axonal transection in the lesions of multiple sclerosis, and " The New England Journal of Medicine, vol. 338, no. 5, pp. 278-285, 1998.
2. J. H. van Waesberghe, W. Kamphorst, C. J. de Groot et al. , and "Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability, and " Annals of Neurology, vol. 46, no. 5, pp. 747-754, 1999.
3. B. Ferguson, M. K. Matyszak, M. M. Esiri, and V. H. Perry, and "Axonal damage in acute multiple sclerosis lesions, and " Brain, vol. 120, no. 3, pp. 393-399, 1997.
4. D. Barnes, P. M. G. Munro, B. D. Youl, J. W. Prineas, andW. I. McDonald, and "The longstanding MS lesion. A quantitative MRI and electron microscopic study, and " Brain, vol. 114, no. 3, pp. 1271- 1280, 1991.
5. J. van Horssen, B. P. Brink, H. E. de Vries, P. Van der Valk, and L. Bo, and "The blood-brain barrier in cortical multiple sclerosis lesions, and " Journal ofNeuropathology and ExperimentalNeurology, vol. 66, no. 4, pp. 321-328, 2007.
6. J. W. Peterson, L. Bö, S. Mörk, A. Chang, and B. D. Trapp, and "Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions, and " Annals of Neurology, vol. 50, no. 3, pp. 389-400, 2001.
7. C. F. Lucchinetti, B. F. G. Popescu, R. F. Bunyan et al. , and "Inflammatory cortical demyelination in early multiple sclerosis, and " The New England Journal ofMedicine, vol. 365, no. 23, pp. 2188-2197, 2011.
8. A. Charil, A. Dagher, J. P. Lerch, A. P. Zijdenbos, K. J. Worsley, and A. C. Evans, and "Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability, and " NeuroImage, vol. 34, no. 2, pp. 509-517, 2007.
9. R. Reynolds, F. Roncaroli, R. Nicholas, B. Radotra, D. Gveric, andO. Howell, and "The neuropathological basis of clinical progression in multiple sclerosis, and " Acta Neuropathologica, vol. 122, no. 2, pp. 155-170, 2011.
10. J. J. Geurts, M. Calabrese, E. Fisher, and R. A. Rudick, and "Measurement and clinical effect of grey matter pathology in multiple sclerosis, and " The Lancet Neurology, vol. 11, no. 12, pp. 1082-1192, 2012.
11. S. Sawcer, and "The complex genetics of multiple sclerosis: pitfalls and prospects, and " Brain, vol. 131, no. 12, pp. 3118-3131, 2008.
12. International Multiple Sclerosis Genetics Consortium, and "MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis, and " Brain, vol. 136, no. 6, pp. 1778-1782, 2013.
13. A. Ascherio and K. L. Munger, and "Environmental risk factors for multiple sclerosis. Part I: the role of infection, and " Annals of Neurology, vol. 61, no. 4, pp. 288-299, 2007.
14. A. Ascherio and K. L. Munger, and "Environmental risk factors for multiple sclerosis. Part II: noninfectious factors, and " Annals of Neurology, vol. 61, no. 6, pp. 504-513, 2007.
15. A. Nylander and D. A. Hafler, and "Multiple sclerosis, and " Journal of Clinical Investigation, vol. 122, no. 4, pp. 1180-1188, 2012.
16. C. Confavreux and S. Vukusic, and "Natural history of multiple sclerosis: a unifying concept, and " Brain, vol. 129, no. 3, pp. 606-616, 2006.
17. D. H. Miller and S. M. Leary, and "Primary-progressive multiple sclerosis, and "TheLancetNeurology, vol. 6, no. 10, pp. 903-912, 2007.
18. C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine, and "Relapses and progression of disability in multiple sclerosis, and " The New England Journal ofMedicine, vol. 343, no. 20, pp. 1430- 1438, 2000.
19. M. Tintoré, A. Rovira, J. Rio et al. , and "Is optic neuritis more benign than other first attacks in multiple sclerosis?" Annals of Neurology, vol. 57, no. 2, pp. 210-215, 2005.
20. E. M. Mowry, S. Deen, I. Malikova, J. Pelletier, P. Bacchetti, and E. Waubant, and "The onset location of multiple sclerosis predicts the location of subsequent relapses, and " Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 4, pp. 400-403, 2009.
21. M. P. Sormani, M. Tintoŕ, M. Rovaris et al. , and "Will Rogers phenomenon inmultiple sclerosis, and " Annals of Neurology, vol. 64, no. 4, pp. 428-433, 2008.
22. M. Eriksson, O. Andersen, and B. Runmarker, and "Long-term follow up of patients with clinically isolated syndromes, relapsingremitting and secondary progressive multiple sclerosis, and " Multiple Sclerosis, vol. 9, no. 3, pp. 260-274, 2003.
23. C. H. Polman, S. C. Reingold, B. Banwell et al. , and "Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, and " Annals of Neurology, vol. 69, no. 2, pp. 292-302, 2011.
24. B. G. Weinshenker, G. P. A. Rice, J. H. Noseworthy, W. Carriere, J. Baskerville, and G. C. Ebers, and "The natural history ofmultiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors andmodels of outcome, and " Brain, vol. 114, no. 2, pp. 1045-1056, 1991.
25. C. Confavreux, S. Vukusic, and P. Adeleine, and "Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process, and " Brain, vol. 126, no. 4, pp. 770-782, 2003.
26. H. Tremlett, D. Paty, and V. Devonshire, and "Disability progression inmultiple sclerosis is slower than previously reported, and " Neurology, vol. 66, no. 2, pp. 172-177, 2006.
27. M. Debouverie, S. Pittion-Vouyovitch, S. Louis, and F. Guillemin, and "Natural history of multiple sclerosis in a population-based cohort, and " European Journal of Neurology, vol. 15, no. 9, pp. 916-921, 2008.
28. H. Tremlett, Y. Zhao, and V. Devonshire, and "Natural history of secondary-progressive multiple sclerosis, and " Multiple Sclerosis, vol. 14, no. 3, pp. 314-324, 2008.
29. S. Vukusic and C. Confavreux, and "Prognostic factors for progression of disability in the secondary progressive phase ofmultiple sclerosis, and " Journal of the Neurological Sciences, vol. 206, no. 2, pp. 135-137, 2003.
30. B. Runmarker and O. Andersen, and "Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up, and " Brain, vol. 116, no. 1, pp. 117-134, 1993.
31. M. W. Koch, M. Uyttenboogaart, A. van Harten, and J. de Keyser, and "Factors associated with the risk of secondary progression in multiple sclerosis, and " Multiple Sclerosis, vol. 14, no. 6, pp. 799-803, 2008.
32. H. Tremlett, M. Yousefi, V. Devonshire, P. Rieckmann, and Y. Zhao, and "Impact of multiple sclerosis relapses on progression diminishes with time, and " Neurology, vol. 73, no. 20, pp. 1616-1623, 2009.
33. M. Filippi, D. W. Paty, L. Kappos et al. , and "Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study, and " Neurology, vol. 45, no. 2, pp. 255-260, 1995.
34. L. Kappos, D. Moeri, E. W. Radue et al. , and "Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis, and " The Lancet, vol. 353, no. 9157, pp. 964-969, 1999.
35. S. Mesaros, M. A. Rocca, M. P. Sormani, A. Charil, G. Comi, and M. Filippi, and "Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS: a large scale, short-term follow-up study, and " Journal of Neurology, vol. 255, no. 9, pp. 1378-1383, 2008.
36. S. A. Gauthier, M. Mandel, C. R. G. Guttmann et al. , and "Predicting short-term disability in multiple sclerosis, and " Neurology, vol. 68, no. 24, pp. 2059-2065, 2007.
37. V. L. Stevenson, G. T. Ingle, D. H. Miller, and A. J. Thompson, and "Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study, and " Multiple Sclerosis, vol. 10, no. 4, pp. 398-401, 2004.
38. M. Sailer, N. A. Losseff, L. Wang, M. L. Gawne-Cain, A. J. Thompson, and D. H. Miller, and "T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study, and " European Journal of Neurology, vol. 8, no. 1, pp. 37-42, 2001.
39. A. Minneboo, B. Jasperse, F. Barkhof et al. , and "Predicting shortterm disability progression in early multiple sclerosis: added value of MRI parameters, and " Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 8, pp. 917-923, 2008.
40. Z. Khaleeli, O. Ciccatelli, F. Manfredonia et al. , and "Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study, and " Annals of Neurology, vol. 63, no. 6, pp. 790- 793, 2008.
41. V. Popescu, F. Agosta, H. E. Hulst et al. , and "Brain atrophy and lesion load predict long term disability in multiple sclerosis, and " Journal of Neurology, Neurosurgery, and Psychiatry, vol. 84, no. 10, pp. 1082-1091, 2013.
42. B. Jasperse, H. Vrenken, E. Sanz-Arigita et al. , and "Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis, and " NeuroImage, vol. 38, no. 3, pp. 529-537, 2007.
43. J. Sepulcre, J. Sastre-Garriga, M. Cercignani, G. T. Ingle, D. H. Miller, and A. J. Thompson, and "Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study, and " Archives of Neurology, vol. 63, no. 8, pp. 1175-1180, 2006.
44. J. T. Chen, S. Narayanan, D. L. Collins, S. M. Smith, P. M. Matthews, and D. L. Arnold, and "Relating neocortical pathology to disability progression in multiple sclerosis using MRI, and " NeuroImage, vol. 23, no. 3, pp. 1168-1175, 2004.
45. L. K. Fisniku, D. T. Chard, J. S. Jackson et al. , and "Gray matter atrophy is related to long-term disability in multiple sclerosis, and " Annals of Neurology, vol. 64, no. 3, pp. 247-254, 2008.
46. S. D. Roosendaal, K. Bendfeldt, H. Vrenken et al. , and "Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability, and " Multiple Sclerosis, vol. 17, no. 9, pp. 1098-1106, 2011.
47. R. A. Rudick, J. -C. Lee, K. Nakamura, and E. Fisher, and "Graymatter atrophy correlates with MS disability progression measured with MSFC but not EDSS, and " Journal of the Neurological Sciences, vol. 282, no. 1-2, pp. 106-111, 2009.
48. M. Calabrese, C. Romualdi, V. Poretto et al. , and "The changing clinical course of multiple sclerosis: a matter of grey matter, and " Annals of Neurology, vol. 74, no. 1, pp. 76-83, 2013.
49. M. Sailer, B. Fischl, D. Salat et al. , and "Focal thinning of the cerebral cortex inmultiple sclerosis, and " Brain, vol. 126, no. 8, pp. 1734-1744, 2003.
50. B. Audoin, G. R. Davies, L. Finisku, D. T. Chard, A. J. Thompson, and D. H. Miller, and "Localization of greymatter atrophy in early RRMS: a longitudinal study, and " Journal of Neurology, vol. 253, no. 11, pp. 1495-1501, 2006.
51. M. Calabrese, M. Atzori, V. Bernardi et al. , and "Cortical atrophy is relevant in multiple sclerosis at clinical onset, and " Journal of Neurology, vol. 254, no. 9, pp. 1212-1220, 2007.
52. R. H. B. Benedict, D. Ramasamy, F. Munschauer, B. Weinstock- Guttman, and R. Zivadinov, and "Memory impairment in multiple sclerosis: correlationwithdeepgreymatter andmesial temporal atrophy, and " Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 2, pp. 201-206, 2009.
53. N. L. Sicotte, K. C. Kern, B. S. Giesser et al. , and "Regional hippocampal atrophy in multiple sclerosis, and " Brain, vol. 131, no. 4, pp. 1134-1141, 2008.
54. M. Calabrese, V. Poretto, A. Favaretto et al. , and "Cortical lesion load associates with progression of disability in multiple sclerosis, and " Brain, vol. 135, no. 10, pp. 2952-2961, 2012.
55. G. J. Lycklama Á Nijeholt, M. A. A. van Walderveen, J. A. Castelijns et al. , and "Brain and spinal cord abnormalities in multiple sclerosis: correlation between MRI parameters, clinical subtypes and symptoms, and " Brain, vol. 121, no. 4, pp. 687-697, 1998.
56. M. Rovaris, M. Bozzali, G. Santuccio et al. , and "Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis, and " Journal of Neurology Neurosurgery and Psychiatry, vol. 69, no. 6, pp. 723-727, 2000
57. N. A. Losseff, S. L. Webb, J. I. ORiordan et al. , and "Spinal cord atrophy and disability inmultiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression, and " Brain, vol. 119, no. 3, pp. 701-708, 1996.
58. M. Rovaris, M. Bozzali, G. Santuccio et al. , and "Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis, and " Journal of Neurology Neurosurgery and Psychiatry, vol. 69, no. 6, pp. 723-727, 2000.
59. F. Agosta, M. Rovaris, E. Pagani, M. P. Sormani, G. Comi, and M. Filippi, and "Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients withmultiple sclerosis, and " Brain, vol. 129, no. 10, pp. 2620-2627, 2006.
60. M. Rovaris, E. Judica, A. Gallo et al. , and "Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years, and " Brain, vol. 129, no. 10, pp. 2628-2634, 2006.
61. M. Calabrese, F. Rinaldi, D. Seppi et al. , and "Cortical diffusiontensor imaging abnormalities in multiple sclerosis: a 3-year longitudinal study, and " Radiology, vol. 261, no. 3, pp. 891-898, 2011.
62. A. Martínez-Yélamos, A. Rovira, R. Sánchez-Valle et al. , and "CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS, and " Journal of Neurology, vol. 251, no. 10, pp. 1278-1279, 2004.
63. M. Colucci, L. Roccatagliata, E. Capello et al. , and "The 14-3-3 protein in multiple sclerosis: a marker of disease severity, and " Multiple Sclerosis, vol. 10, no. 5, pp. 477-481, 2004.
64. F. G. Joseph, C. L. Hirst, T. P. Pickersgill, Y. Ben-Shlomo, N. P. Robertson, and N. J. Scolding, and "CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients, and " Journal ofNeurology, Neurosurgery and Psychiatry, vol. 80, no. 3, pp. 292-296, 2009.
65. N. Norgren, P. Sundström, A. Svenningsson, L. Rosengren, T. Stigbrand, and M. Gunnarsson, and "Neurofilament and glial fibrillary acidic protein inmultiple sclerosis, and " Neurology, vol. 63, no. 9, pp. 1586-1590, 2004.
66. J. Salzer, A. Svenningsson, and P. Sundström, and "Neurofilament light as a prognostic marker in multiple sclerosis, and " Multiple Sclerosis, vol. 16, no. 3, pp. 287-292, 2010.
67. A. Petzold, M. J. Eikelenboom, G. Keir et al. , and "Axonal damage accumulates in the progressive phase ofmultiple sclerosis: three year follow up study, and " Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 2, pp. 206-211, 2005.
68. K. Rejdak, A. Petzold, Z. Stelmasiak, and G. Giovannoni, and "Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis, and " Multiple Sclerosis, vol. 14, no. 1, pp. 59-66, 2008.
69. L. M. Villar, N. García-Barragán, M. Espin∼o et al. , and "Influence of oligoclonal IgM specificity in multiple sclerosis disease course, and " Multiple Sclerosis, vol. 14, no. 2, pp. 183-187, 2008.
70. J. Mandrioli, P. Sola, R. Bedin, M. Gambini, and E. Merelli, and "A multifactorial prognostic index in multiple sclerosis: cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease, and " Journal of Neurology, vol. 255, no. 7, pp. 1023-1031, 2008.
71. M. Comabella, M. Fernández, R. Martin et al. , and "Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis, and " Brain, vol. 133, no. 4, pp. 1082-1093, 2010.
72. A. Gajofatto, S. Monaco, M. Fiorini et al. , and "Assessment of outcome predictors in first-episode acute myelitis a retrospective study of 53 cases, and " Archives of Neurology, vol. 67, no. 6, pp. 724- 730, 2010.
73. H. Tremlett, Y. Zhao, P. Rieckmann, and M. Hutchinson, and "New perspectives in the natural history of multiple sclerosis, and " Neurology, vol. 74, no. 24, pp. 2004-2015, 2010.
74. A. Gajofatto, M. Bongianni, G. Zanusso et al. , and "Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis, and " Acta Neurologica Scandinavica, vol. 128, no. 5, pp. 336-344, 2013.
75. A. E. Hensiek, S. R. Seaman, L. F. Barcellos et al. , and "Familial effects on the clinical course of multiple sclerosis, and " Neurology, vol. 68, no. 5, pp. 376-383, 2007.
76. C. Confavreux and S. Vukusic, and "Age at disability milestones in multiple sclerosis, and " Brain, vol. 129, no. 3, pp. 595-605, 2006.
77. C. Renoux, S. Vukusic, Y. Mikaeloff et al. , and "Natural history of multiple sclerosis with childhood onset, and " The New England Journal of Medicine, vol. 356, no. 25, pp. 2603-2613, 2007.
78. M. Tutuncu, J. Tang, N. A. Zeid et al. , and "Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis, and " Multiple Sclerosis, vol. 19, no. 2, pp. 188-198, 2013.
79. A. Scalfari, A. Neuhaus, A. Degenhardt et al. , and "The natural history of multiple sclerosis, a geographically based study 10: relapses and long-termdisability, and " Brain, vol. 133, no. 7, pp. 1914- 1929, 2010.
80. M. Hutchinson, and "Truly benign multiple sclerosis is rare: Lets stop fooling ourselves-commentary, and "Multiple Sclerosis, vol. 18, no. 1, p. 15, 2012.
81. J. F. Kurtzke, and "Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS), and " Neurology, vol. 33, no. 11, pp. 1444-1452, 1983.
82. F. D. Lublin and S. C. Reingold, and "Defining the clinical course of multiple sclerosis: results of an international survey, and " Neurology, vol. 46, no. 4, pp. 907-911, 1996.
83. S. J. Pittock, R. L. McClelland, W. T. Mayr et al. , and "Clinical implications of benignmultiple sclerosis: a 20-year populationbased follow-up study, and " Annals of Neurology, vol. 56, no. 2, pp. 303-306, 2004.
84. M. P. Amato, E. Portaccio, M. L. Stromillo et al. , and "Cognitive assessment and quantitative magnetic resonance metrics can help to identify benignmultiple sclerosis, and " Neurology, vol. 71, no. 9, pp. 632-638, 2008.
85. A. -L. Sayao, V. Devonshire, and H. Tremlett, and "Longitudinal follow-up of and "benign" multiple sclerosis at 20 years, and " Neurology, vol. 68, no. 7, pp. 496-500, 2007.
86. G. S. M. Ramsaransing and J. de Keyser, and "Predictive value of clinical characteristics for and "benign" multiple sclerosis, and " European Journal of Neurology, vol. 14, no. 8, pp. 885-889, 2007.
87. E. Leray, M. Coustans, E. Le Page, J. Yaouanq, J. Oger, and G. Edan, and "Clinically definite benign multiple sclerosis, an unwarranted conceptual hodgepodge: evidence from a 30-year observational study, and " Multiple Sclerosis, vol. 19, no. 4, pp. 458- 465, 2013.
88. L. Costelloe, A. Thompson, C. Walsh, N. Tubridy, and M. Hutchinson, and "Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease, and " Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 11, pp. 1245-1248, 2008.
89. P. OConnor, P. Marchetti, L. Lee, and M. Perera, and "Evoked potential abnormality scores are a useful measure of disease burden in relapsing-remitting multiple sclerosis, and " Annals of Neurology, vol. 44, no. 3, pp. 404-407, 1998.
90. P. Fuhr, A. Borggrefe-Chappuis, C. Schindler, and L. Kappos, and "Visual and motor evoked potentials in the course of multiple sclerosis, and " Brain, vol. 124, no. 11, pp. 2162-2168, 2001.
91. L. Leocani, M. Rovaris, F. M. Boneschi et al. , and "Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study, and " Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 9, pp. 1030-1035, 2006.
92. B. A. Kallmann, S. Fackelmann, K. V. Toyka, P. Rieckmann, and K. Reiners, and "Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis, and " Multiple Sclerosis, vol. 12, no. 1, pp. 58-65, 2006.
93. P. Invernizzi, L. Bertolasi, M. R. Bianchi, M. Turatti, A. Gajofatto, and M. D. Benedetti, and "Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score, and " Journal of Neurology, vol. 258, no. 11, pp. 1933-1939, 2011.
94. R. Schlaeger, M. DSouza, C. Schindler et al. , and "Prediction of long-termdisability inmultiple sclerosis, and "Multiple Sclerosis, vol. 18, no. 1, pp. 31-38, 2012.
95. R. Pelayo, X. Montalban, T. Minoves et al. , and "Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?" Multiple Sclerosis, vol. 16, no. 1, pp. 55-61, 2010.
96. A. Petzold, J. F. de Boer, S. Schippling et al. , and "Optical coherence tomography inmultiple sclerosis: a systematic reviewand metaanalysis, and " The Lancet Neurology, vol. 9, no. 9, pp. 921-932, 2010.
97. K. L. Young, A. U. Brandt, A. Petzold et al. , and "Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis, and " European Journal of Neurology, vol. 20, no. 5, pp. 803-811, 2013.
98. J. N. Ratchford, S. Saidha, E. S. Sotirchos et al. , and "Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning, and " Neurology, vol. 80, no. 1, pp. 47-54, 2013.
99. S. Saidha, S. B. Syc, M. A. Ibrahim et al. , and "Primary retinal pathology inmultiple sclerosis as detected by optical coherence tomography, and " Brain, vol. 134, no. 2, pp. 518-533, 2011.
100. P. Albrecht, M. Ringelstein, A. K. Müller et al. , and "Degeneration of retinal layers inmultiple sclerosis subtypes quantified by optical coherence tomography, and " Multiple Sclerosis, vol. 18, no. 10, pp. 1422-1429, 2012.
101. F. Fazekas, P. Soelberg-Sorensen, G. Comi, and M. Filippi, and "MRI to monitor treatment efficacy in multiple sclerosis, and " Journal of Neuroimaging, vol. 17, supplement s1, pp. 50S-55S, 2007.
102. P. A. Brex, O. Ciccarelli, J. I. ORiordan, M. Sailer, A. J. Thompson, and D. H. Miller, and "A longitudinal study of abnormalities on MRI and disability from multiple sclerosis, and " The New England Journal of Medicine, vol. 346, no. 3, pp. 158-164, 2002.
103. M. Filippi, M. A. Horsfield, S. P. Morrissey et al. , and "Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis, and " Neurology, vol. 44, no. 4, pp. 635-641, 1994.
104. F. Pérez-Miralles, J. Sastre-Garriga, M. Tintoré et al. , and "Clinical impact of early brain atrophy in clinically isolated syndromes, and " Multiple Sclerosis, 2013.
105. M. A. Rocca, S. Mesaros, E. Pagani, M. P. Sormani, G. Comi, and M. Filippi, and "Thalamic damage and long-term progression of disability in multiple sclerosis, and " Radiology, vol. 257, no. 2, pp. 463-469, 2010.
106. A. Kutzelnigg, J. C. Faber-Rod, J. Bauer et al. , and "Widespread demyelination in the cerebellar cortex in multiple sclerosis, and " Brain Pathology, vol. 17, no. 1, pp. 38-44, 2007.
107. M. Calabrese, I. Mattisi, F. Rinaldi et al. , and "Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis, and " Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 4, pp. 401-404, 2010.
108. M. Calabrese, P. Grossi, A. Favaretto et al. , and "Cortical pathology inmultiple sclerosis patients with epilepsy: a 3 year longitudinal study, and " Journal of Neurology, Neurosurgery and Psychiatry, vol. 83, no. 1, pp. 49-54, 2012.
109. G. Lycklama, A. Thompson, M. Filippi et al. , and "Spinal-cord MRI in multiple sclerosis, and " The Lancet Neurology, vol. 2, no. 9, pp. 555-562, 2003.
110. F. Agosta, M. Absinta, M. P. Sormani et al. , and "In vivo assessment of cervical cord damage inMS patients: a longitudinal diffusion tensor MRI study, and " Brain, vol. 130, no. 8, pp. 2211-2219, 2007.
111. A. Martínez-Yélamos, A. Saiz, J. Bas, J. J. Hernandez, F. Graus, and T. Arbizu, and "Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsingremitting multiple sclerosis, and " Neuroscience Letters, vol. 363, no. 1, pp. 14-17, 2004.
112. J. Brettschneider, H. Tumani, U. Kiechle et al. , and "IgG antibodies against measles, rubella, and varicella zoster virus predict conversion tomultiple sclerosis in clinically isolated syndrome, and " PLoS ONE, vol. 4, no. 11, Article ID e7638, 2009.
113. M. Khademi, I. Kockum, M. L. Andersson et al. , and "Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course, and " Multiple Sclerosis, vol. 17, no. 3, pp. 335-343, 2011.
114. C. E. Teunissen, P. C. Dijkstra, and C. Polman, and "Biological markers in CSF and blood for axonal degeneration in multiple sclerosis, and " The Lancet Neurology, vol. 4, no. 1, pp. 32-41, 2005.
115. A. Gajofatto, M. Bongianni, G. Zanusso, M. D. Benedetti, and S. Monaco, and "Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?" International Journal of Molecular Sciences, vol. 12, no. 11, pp. 7960-7970, 2011.
116. E. Kapaki, G. P. Paraskevas, M. Michalopoulou, and K. Kilidireas, and "Increased cerebrospinal fluid tau protein in multiple sclerosis, and " European Neurology, vol. 43, no. 4, pp. 228-232, 2000.
117. H. Bartosik-Psujek and J. J. Archelos, and "Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlatewith intrathecal synthesis of IgG, and " Journal of Neurology, vol. 251, no. 4, pp. 414-420, 2004.
118. J. Brettschneider, M. Maier, S. Arda et al. , and "Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis, and " Multiple Sclerosis, vol. 11, no. 3, pp. 261-265, 2005.
119. M. Terzi, A. Birinci, E. C etinkaya, and M. K. Onar, and "Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis, and "ActaNeurologica Scandinavica, vol. 115, no. 5, pp. 325- 330, 2007.
120. J. Frederiksen, K. Kristensen, J. M. C. Bahl, andM. Christiansen, and "Tau protein: a possible prognostic factor in optic neuritis and multiple sclerosis, and "Multiple Sclerosis, vol. 18, no. 5, pp. 592-599, 2012.
121. F. J. Jiménez-Jiménez, J. M. Zurdo, A. Hernanz et al. , and "Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis, and " Acta Neurologica Scandinavica, vol. 106, no. 6, pp. 351-354, 2002.
122. J. Guimara∼es, M. J. Cardoso, andM. J. Sá, and "Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis, and "Multiple Sclerosis, vol. 12, no. 3, pp. 354-356, 2006.
123. C. E. Teunissen, E. Iacobaeus, M. Khademi et al. , and "Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis, and " Neurology, vol. 72, no. 15, pp. 1322-1329, 2009.
124. M. Fiorini, G. Zanusso, M. D. Benedetti, P. G. Righetti, and S. Monaco, and "Cerebrospinal fluid biomarkers in clinically isolated syndromes and multiple sclerosis, and " Proteomics, vol. 1, no. 9, pp. 963-971, 2007.
125. J. Jaworski, M. Psujek, M. Janczarek, M. Szczerbo-Trojanowska, and H. Bartosik-Psujek, and "Total-tau in cerebrospinal fluid of patients withmultiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy, and " Upsala Journal of Medical Sciences, vol. 117, no. 3, pp. 284-292, 2012.
126. N. de Stefano, A. Giorgio, M. Battaglini et al. , and "Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes, and " Neurology, vol. 74, no. 23, pp. 1868-1876, 2010.
127. J. de Seze, K. Peoch, D. Ferriby, T. Stojkovic, J. -L. Laplanche, and P. Vermersch, and "14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis, and " Journal of Neurology, vol. 249, no. 5, pp. 626-627, 2002.
128. K. Hein (néeMaier), A. Köhler, R. Diem et al. , and "Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis, and " Neuroscience Letters, vol. 436, no. 1, pp. 72-76, 2008.
129. C. Malmeström, S. Haghighi, L. Rosengren, O. Andersen, and J. Lycke, and "Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS, and " Neurology, vol. 61, no. 12, pp. 1720-1725, 2003.
130. J. Kuhle, D. Leppert, A. Petzold et al. , and "Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis, and " Neurology, vol. 76, no. 14, pp. 1206-1213, 2011.
131. M. Khalil, C. Enzinger, C. Langkammer et al. , and "CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome, and " Multiple Sclerosis, vol. 19, no. 4, pp. 436- 442, 2013.
132. B. Bielekova and R. Martin, and "Development of biomarkers in multiple sclerosis, and " Brain, vol. 127, no. 7, pp. 1463-1478, 2004.
133. C. E. Teunissen, A. Petzold, J. L. Bennett et al. , and "A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking, and " Neurology, vol. 73, no. 22, pp. 1914-1922, 2009.
134. C. Teunissen, T. Menge, A. Altintas et al. , and "Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies inmultiple sclerosis, and "Multiple Sclerosis, 2013.